Owkin
Andrew Pierce is an accomplished professional in the field of translational medicine and oncology, currently serving as Senior Vice President - Discovery & Development at Owkin since April 2024. Prior experience includes roles as Vice President - Translational Biology at Crescendo Biologics Limited, and Associate Director - Translational Medicine Oncology at AstraZeneca, where Andrew led a molecular pathology laboratory and developed clinical biomarker strategies. Andrew's career began with postdoctoral research at Duke University and Memorial Sloan-Kettering Cancer Center, focusing on DNA repair mechanisms, followed by an academic position as Assistant Professor at the University of Kentucky. Andrew holds a Ph.D. in molecular genetics from the University of North Carolina at Chapel Hill and a B.Sc. (honors) in Molecular and Cellular Biology from the University of Toronto.
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.